United States of America v. Shiel Medical Laboratory

CourtDistrict Court, E.D. New York
DecidedFebruary 26, 2024
Docket1:16-cv-01090
StatusUnknown

This text of United States of America v. Shiel Medical Laboratory (United States of America v. Shiel Medical Laboratory) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States of America v. Shiel Medical Laboratory, (E.D.N.Y. 2024).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK UNITED STATES OF AMERICA, ex rel. YNKDY- MEMORANDUM & ORDER 2; STATE OF NEW YORK, ex rel. YNKDY-2; 16-CV-1090 (NGG) (TAM) STATE OF NEW JERSEY, ex rel. YNKDY-2, “CV-1090 ( Relator, -against- SHIEL MEDICAL LABORATORY; SHIEL HOLDINGS, LLC; FRESENIUS MEDICAL CARE; BIM MEDICAL, INC.; JACK BASCH; FRESENIUS MEDICAL CARE HOLDINGS, INC.; SPECTRA HOLDCO, LLC; DOES 3-10, Inclusive, et al., Defendants.

NICHOLAS G. GARAUFIS, United States District Judge. Now before the court in this qui tam action is Relator YNKDY-2’s! motion for leave to file their Fourth Amended Complaint. (Not. of Mot. to Amend (Dkt. 100); Mem. of Law in Support of Mot. to Amend (“Mot.”) (Dkt. 100-1); Proposed Fourth Amended Com- plaint (“Proposed Fourth Am, Compl.”) (Dkt. 100-2}.) For the reasons discussed, Relator’s motion is GRANTED.

1 YNKDY-2 is a California corporation owned and created by James Gor- don. (Third Am. Compl. (Dkt. 65) { 9; Reply (Dkt. 106) at 13.) Relator asserts that filing the present action as YNKDY-2 rather than as Gordon was necessary to protect Gordon’s identity and his family. (Reply at 13- 14.)

I. BACKGROUND A. Factual Background and Claims In the Third Amended Complaint, Relator alleges, inter alia, that Defendant Shiel Medical Laboratory (“Shiel”) and its successors” submitted hundreds of millions of dollars in false claims to the Medicare and New York and New Jersey Medicaid programs for tests that were neither reasonable nor necessary. (Third Am. Compl. (“TAC”) (Dkt. 65) "| 4.) Defendants did this by falsely submitting diagnostic codes to trigger Medicare or Medicaid re- imbursement, (id. 81-91), and knowingly submitting false claims for unnecessary tests, Cid. €{ 92-95.) Relator further al- leges that these unnecessary tests arose from referrals based on improper financial relationships and kickbacks involving physi- cians and nursing facilities. Ud. {4 4, 96.) After the filing of this complaint in January 2017, James Gordon, referred to as John Doe in the TAC, was fired from Fresenius in February 2017. Cd. "| 173-74; Proposed Fourth Am. Compl, 14 222-38.) B. Procedural History Relator is now seeking to file their Fourth Amended Complaint. Relator filed its initial complaint on March 4, 2016. (Compl. (Dkt. 1).) A year later, while the case was still under seal, Relator filed their First Amended Complaint. (First Am. Compl. (Dkt. 9).) On February 9, 2022, Relator then filed a Second Amended Com- plaint after the court granted leave to do so under Fed. R. Civ. P. 15(a}(2). (Second Am. Compl. (Dkt. 22}; see also Min. Entry dated December 28, 2021.) The case was then unsealed on June

2 Shiel’s laboratory business was purchased in 2013 by Defendant Frese- nus Medical Care of North America (“Fresenius”), (Third Amended Complaint (“TAC”) (Dkt. 65) 1 2.} The same year, Shiel became BIM Med- ical, Inc. Ud.) Defendant Jack Basch is an owner as well as President and CEO of BIM Medical, Inc. Ud. 9] 2, 12.) Defendant Spectra Holdco, LLC (“Spectra”), was also named as related to Defendants Shiel and Fresenius. (id. 17,)

14, 2022, after the United States and the States of New York, New Jersey, and Connecticut elected to decline intervention. (Or- der to Unseal (Dkt. 28); see also Dkts. 24-27.) Once unsealed, Relator filed their Third Amended Complaint in May 2023, on consent of the parties, to substitute John Doe Defendants for De- fendants Fresenius and Spectra. (TAC; see also Mot. at 2; Min. Entry dated May 9, 2023.) The Third Amended Complaint includes the following claims based on Defendants’ alleged fraudulent schemes: (1) presenta- tions of false claims under 31 U.S.C. §8 3729 (a)(1) and (A) of the FCA; (2) false statements material to false claims under § 3729(a)(1)(B) of the FCA; (3) failure to return overpay- ments under § 3729(a)(1)(B) of the FCA; (4) violation of the New York False Claims Act claims under New York State Finance Law, Art. XTI 88 187 et seq.; (5) violation of the New Jersey False Claims Act claims under N.J. Stat. Ann. § 2A:32C-3; (6) illegal retaliation on behalf of non-party John Doe under 31 U.S.C, §3730(h) of the FCA; and (7) illegal retaliation on behalf of John Doe under the New Jersey Conscientious Employee Protection Act, N.S.A, 34:19-1, et. seg. (TAC 94 127-181.) In September 2023, this court held a pre-motion conference in which it set a briefing schedule for Defendants’ motion to dismiss Relator’s Third Amended Complaint. (Min. Entry dated Septem- ber 7, 2023.) In November 2023, after being served Defendants’ motions to dismiss, and before filing its response, Relator filed a “Fourth Amended Complaint” without first seeking the court's leave to do so. (Dkt. 91.) The court struck this filing, finding that Relator was not permitted to file an amended complaint as a mat- ter of course under Rule 15(a)(1), having already filed multiple amended complaints on consent or with the court’s permission. (Min. Entry dated November 22, 2023.) Relator then made the present motion seeking leave to file their Fourth Amended Com- plaint. (See Not. of Mot. to Amend; Mot.; see also Fresenius

Response (Dkt. 101); BIM Response (Dkt. 102); Basch Response (Dkt. 103); Reply (Dkt. 106).) Ii, LEGAL STANDARD Leave to amend should be “freely give[n] . . . when justice so requires,” Fed. R. Civ. P. 15(a)(2). “This permissive standard is consistent with [the Second Circuit’s] strong preference for re- solving disputes on the merits.” Williams v. Citigroup Inc., 659 F.3d 208, 212-13 (2d Cir. 2011). Although leave to amend is liberally granted, it “may properly be denied for: undue delay, bad faith or dilatory motive on the part of the movant, repeated failure to cure deficiencies by amend- ments previously allowed, undue prejudice to the opposing party by virtue of allowance of the amendment, futility of amendment, etc.” Ruotolo v. N.Y., 514 F.3d 184, 191 (2d Cir. 2008).° The “non-movant bears the burden of showing prejudice, bad faith and futility of the amendment.” Grant v. Citibank (S.D.), N.A., 2010 WL 5187754, at *6 (S.D.N.Y. Dec. 6, 2010). “Mere delay . .. absent a showing of bad faith or undue prejudice, does not provide a basis for the district court to deny the right to amend.” Ruotolo, 514 F.3d at 191. Courts will normally grant leave to amend if no prejudice is found. 6A Charles Alan Wright & Arthur R. Miller et al., Federal Practice & Procedure § 1484 (3d ed, 2021}. An amendment prej- udices a non-moving party when, among other things, “the assertion of the new claim or defense would (i) require the op- ponent to expend significant additional resources to conduct discovery and prepare for trial [or] (ii) significantly delay the res- olution of the dispute.” Monahan v. N.Y.C. Dep’t of Corr., 214 F.3d 275, 284 (2d Gir. 2000).

3 When quoting cases, and unless otherwise noted, all citations and quota- tion marks are omitted, and all alterations are adopted.

Ultimately, “fa] district court has broad discretion in determining whether to grant leave to amend[.]” U.S. ex rel. Ladas v. Exelis, Inc., 824 F.3d 16, 28 (2d Cir. 2016). II.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Williams v. Citigroup Inc.
659 F.3d 208 (Second Circuit, 2011)
Ruotolo v. City of New York
514 F.3d 184 (Second Circuit, 2008)
In Re Eaton Vance Mutual Funds Fee Litigation
403 F. Supp. 2d 310 (S.D. New York, 2005)
Saxholm AS v. Dynal, Inc.
938 F. Supp. 120 (E.D. New York, 1996)
United States Ex Rel. Ladas v. Exelis, Inc.
824 F.3d 16 (Second Circuit, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
United States of America v. Shiel Medical Laboratory, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-of-america-v-shiel-medical-laboratory-nyed-2024.